ADIM
GILD icon

Alpha DNA Investment Management’s Gilead Sciences GILD Stock Holding History

Alpha DNA Investment Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,083
Closed -$1.38M – 170
2022
Q4 		$1.38M Buy
+16,083
New +$1.27M 0.49% 46
2021
Q2 		– Sell
-675
Closed -$43K – 313
2021
Q1 		$43K Sell
675
-133
-16% -$8.58K 0.05% 192
2020
Q4 		$47K Buy
+808
New +$48.8K 0.05% 188

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpha DNA Investment Management's GILD Position: Q1 2023 in Review

Alpha DNA Investment Management sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 16,083 shares — an estimated $1.38M sold.

Alpha DNA Investment Management first reported a position in GILD in Q4 2020 and held it in 3 quarters. The position peaked at $1.38M in Q4 2022. 1,736 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

  • Alpha DNA Investment Management reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 16,083 Gilead Sciences shares in Q1 2023, an estimated $1.38M.
  • Alpha DNA Investment Management first reported a position in Gilead Sciences in Q4 2020 and held it in 3 quarters.
  • Alpha DNA Investment Management's Gilead Sciences position peaked at $1.38M in Q4 2022.
  • 1,736 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Alpha DNA Investment Management's 13F filing for Q1 2023, filed 5 May 2023.